On 29 September 2026 the US FDA recorded a supplement to abbreviated new drug application 206433, a generic clozapine held by Aurobindo Pharma. The public record does not state what the supplement changed; supplements to generic applications usually concern manufacturing, labelling alignment or packaging.
This does not create a new indication, and it is not a safety communication. Clozapine's monitoring requirements are unchanged by it. Aurobindo is an Indian manufacturer, but the FDA action applies to the US market; CDSCO's position on this specific product is not stated in the record.
- No change to clozapine indications or monitoring follows from this notice.
- Keep neutrophil monitoring as your local protocol requires.
- When a patient's clozapine supply changes manufacturer, consider a plasma level if symptoms or side effects shift.
- Check the record for detail before telling patients anything has changed.
Why it matters
Generic clozapine supply is routine news, and it should not prompt switching or alarm.
Don't overread it
A licence supplement is not a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free